AltruBio
Latest round
- Series B
Last raised
- May 2024
Total raised
- $288M
Investors
- 8
About AltruBio
, formerly known as AbGenomics Holding Inc. operates as a clinical-stage biotechnology that focuses on the discovery and development of targeted antibody therapeutics for the treatment of cancer and immune-related inflammatory diseases. It has a R&D centre in Taipei. The chairman and CEO of the company, Judy Chou graduated from Yale University and has worked in Bayer AG, Pfizer, and Medivation. The company mainly provides anti-immune inflammation drug ALTB-168, which is a humanized therapeutic target antibody. ALTB-168 can be used to treat diseases such as psoriasis, psoriatic arthritis, ulcerative colitis, and GVHD (Graft-versus-host disease). AltruBio also provides immunity drug candidates ALTB-268, which can be used to treat ulcerative colitis and psoriatic arthritis.
Who invested in AltruBio
8 investors across 2 rounds
See all investors in AltruBio
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about AltruBio
Who invested in AltruBio?
AltruBio has 8 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has AltruBio raised?
AltruBio has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did AltruBio last raise money?
AltruBio's most recent round on record is a Series B, in May 2024.
What does AltruBio do?
, formerly known as AbGenomics Holding Inc.
Where is AltruBio headquartered?
AltruBio is headquartered in San Francisco, US.
Which VCs invest in companies like AltruBio?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at AltruBio's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like AltruBio? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.